C ardiovascular disease (CVD) is the most common cause of death in the developed world, 1 and identification of those at high risk and strategies to reduce its incidence are important goals. Risk factors for CVD are numerous and well characterized, allowing groups at higher risk to be identified. Markers of preclinical disease may provide greater use for studying the development of CVD compared with traditional clinical and lifestyle-related risk factors.
Genome-wide association studies have identified numerous loci implicated in CVD and related traits, 6 but translating these initial findings into information about molecular processes and clinical utility has often been problematic 7 ; several CV risk factors have been identified which predict the development of complications. Markers of preclinical disease, however, are of greater use for understanding the evolution of arterial disease and for the development of prevention strategies. Use of carotid intima-media thickness (cIMT) in genome-wide association studies may provide new information about pathways to cardiovascular disease, allowing new loci to be found and investigated for their molecular basis.
Gertow et al 8 performed a genomic scan using the genecentric CardioMetabochip in the European IMT and IMTProgression as Predictors of Vascular Events (IMPROVE) cohort, a longitudinal multicentre observational study designed to look at IMT as a predictor of vascular events. A locus on chromosome 16 was robustly associated with IMT and coronary artery disease risk in 3711 participants. The minor A allele of the lead single nucleotide polymorphism (SNP), rs4888378, was protective, being associated with lower cIMT and lower coronary artery disease risk. This variant is located within intron 6, near the 3′ end of the CFDP1 gene (craniofacial development protein 1); located upstream are the genes TMEM170A and CHST6, and downstream are BCAR1, CTRB1, and CTRB2 ( Figure I in the Data Supplement). The lead SNP also showed allelic differences in expression in plaque and aortic tissues for 3 genes at the locus: TMEM170A, BCAR1, and LDHD.
Explaining the molecular mechanisms of this variant is important to understand how disruption of gene expression or protein structure affects molecular processes and disease end points. Extensive linkage disequilibrium (LD) in the genome hinders efforts to identify functional variation, with variants in strong LD showing similar associations with phenotypic traits. Other data must be used to establish their likelihood of functionality, and projects such as ENCODE, Encyclopedia of DNA Elements which map large amounts of functional data onto the genome, allow prioritization of genomic sequences for potential functionality. 9 Here, we describe analysis of the chromosome 16 locus associated with cIMT and coronary artery disease, using bioinformatics and in vitro functional assays to propose a functional SNP, and investigate its association with other cardiometabolic risk factors.
Methods

Study Cohorts
IMPROVE is a prospective multicentre longitudinal study set up to investigate cIMT in individuals at high risk of CVD. 10 Three thousand seven hundred eleven participants (54-79 years) with at least 3 vascular risk factors were recruited in 7 centers in Finland, France, Italy, The Netherlands, and Sweden. IMT variables were measured using ultrasonic scans; presence of plaque was defined as maximum IMT in the whole carotid tree >1.5 mm. 11 The study was designed in accordance with the rules of Good Clinical Practice and with the ethical principles established in the Declaration of Helsinki. Each participant provided 2 different informed consents; 1 for general participation in the study and 1 for genotyping. Progressione della Lesione Intimale Carotidea (PLIC) comprises 2144 general population participants attending the Centre for the Study of Atherosclerosis, Bassini Hospital (Cinisello Balsamo, MI, Italy). The study was designed to study atherosclerotic lesions and IMT in the common carotid artery and relationships with cardiovascular risk factors. Patient characteristics, blood biomarkers, and lifestyle behaviors were recorded and cIMT measured using ultrasound, as published previously. [12] [13] [14] Informed consent was obtained from each patient and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee. Characteristics of IMPROVE and PLIC are shown in Tables I  and II in the Data Supplement. Three additional cohorts were used for replication: Whitehall II (WHII), Edinburgh Artery Study (EAS), and the cardiovascular arm of the Malmö Diet and Cancer study (MDC), the characteristics of which have been described previously. 5, 15, 16 Genotyping rs4888378 was genotyped in PLIC using Life Technologies' TaqMan SNP genotyping assays. Assay mix was dispensed over 5 ng dry DNA and thermocycled as per manufacturers' instructions and fluorescence detected with the ABI 7900HT.
Bioinformatics
1000 Genomes project data with Broad Institute's SNAP (SNP Annotation and Proxy Search) were used to identify variants in strong LD (r 2 ≥0.8) with the lead SNP, rs4888378. 17, 18 These variants were examined for regulatory annotations from ENCODE Project and RoadMap Epigenomics data. 9, 19 The UCSC Genome Browser was used for visualization of variant location. 20 Criteria for variant selection comprise location within narrow peaks for transcription factor binding sites (as assigned from chromatin immunoprecipitation sequencing data), within narrow peaks for DNase-I hypersensitivity, and within either promoter or enhancer histone signatures (defined by H3K4me1, H3K4me3, and H3K27Ac). The ElDorado tool (Genomatix) was used to select variants with only with strong motif changes (thresholds were core similarity of 1 and matrix similarity of >0.8).
The Genotype-Tissue Expression (GTEx) portal 21 was used to calculate the association between rs4888378 genotype and expression of the 9 closest genes to the SNP in the 2 blood vessel-related tissues (aorta and tibial artery). All genes within 200 kb were analyzed, following the approach of Gertow et al using the Advanced Study of Aortic Pathology (ASAP) and Biobank of Karolinska Endarterectomies (biKE) studies (see Discussion).
Cell Culture and Nuclear Extract
Huh7 (human hepatoma) cells were obtained from the European Collection of Cell Cultures (ECACC) and cultured in Dulbecco's Modified Eagle Medium containing 10% FBS. Cells were maintained at 37°C, 5% CO 2 . Nuclear extract for electrophoretic mobility shift assay (EMSA) was obtained from Huh7 cells by the following method. One T-175 flask of cells was grown to 100% confluence. Culture medium was removed and cells washed with 15 mL 1×PBS and trypsinized. A 15-mL serum-containing medium was added to the flask and the cell-medium solution centrifuged at 4°C, 1500 rpm, for 5 minutes. The pellet was resuspended in 5 mL ice-cold buffer A (1 mL 10 M HEPES, pH 7.9; 150 mL 1.5 mmol/L MgCl 2 ; 500 mL 10 mmol/L KCl; and 50 mL 100× protease inhibitor [Thermo Scientific Protease Inhibitor Cocktail Kit]) and left on ice for 10 minutes. Cells were again centrifuged at 4°C, 1500 rpm, for 5 minutes, supernatant discarded, and the pellet resuspended in 2 mL buffer A (10 mmol/L HEPES [pH 7.9], 1.5 mmol/L MgCl 2 , 10 mmol/L KCl).
Cells were vortexed and centrifuged at 4°C, 13 000 rpm, for 2 minutes. Supernatant was discarded and the pellet resuspended in 800 µL buffer C (2 mL 20 mmol/L HEPES, pH 7.9; 50 mL 25% v/v glycerol; 10.5 mL 0.42 M NaCl; 150 mL 1.5 mmol/L MgCl2; 40 mL 0.2 mmol/L EDTA) with 8 µL protease inhibitor. The solution was vortexed for 1 minute and left on ice for 10 minutes; this step was repeated for a total of 4 times. The mix was then centrifuged at 4°C and 13 000 rpm for 50 minutes, and the supernatant was stored at −80°C. October 2015
Electrophoretic Mobility Shift Assay
Double-stranded, 3′-biotinylated oligonucleotides were generated to comprise the 25 bp flanking each candidate SNP for both reference and alternative alleles (probe sequences in Table III in the Data Supplement). Oligos were incubated at 25°C for 50 minutes with Huh7 nuclear extract either with or without competitor (nonbiotinylated double-stranded probe of the same sequence). Complexes were run on a 6% polyacrylamide gel, transferred onto Hybond+ nylon membrane and visualized according to the instructions of the ThermoScientific Lightshift Chemiluminescent Nucleic Acid Detection Module.
Multiplexed competitor EMSA 22 was performed as above, but rather than the same SNP sequence, competitor oligonucleotides consisted of known consensus sequences for common transcription factors (oligo sequences are shown in Table IV in the Data Supplement). Competitors were combined into cocktails of 10 and incubated with nuclear extract; cocktails which competed out a binding protein were identified and their constituent individual competitors incubated separately to identify the competing sequence.
Luciferase Reporter Assay
Four different sequence fragments of 100-379 bp, encompassing the rs4888378 SNP and containing either the G or A allele, were amplified from genomic DNA (fragments are shown in Figure 1 ; cloning primers and pGL3 restriction sites shown in Table V in the Data Supplement). The first fragment was designed to include annotated functional sequence elements close to the SNP. MatInspector 23 was used to predict binding sites in the sequence for proteins classified as repressor or repressor related, and the 3 further fragments were designed to include or exclude these binding sites (shown in Figure 1 ). The pGL3 promoter vector was used for analysis, and the 4 sequence fragments with both alleles were subcloned into the enhancer region: luciferase 3′ untranslated region of the pGL3-promoter.
Huh7 cells in a 96-well format (4×10 4 cells/well) were used for transient transfection. Two hundred nanogram of reporter plasmid DNA, 4 ng Renilla pRL-TK cotransfectant (Promega), and 0.5 µL Lipofectamine 2000 (Invitrogen) were added for transfection in OptiMem reduced serum medium (Life technologies). After 48 hours, cells were lysed, and firefly and Renilla luciferase activity was detected following the instructions of Promega's Dual-Luciferase Reporter Assay System, using Applied Biosystems' TR717 Microplate Luminometer. Results are reported as relative luciferase activity, calculated as a ratio of firefly luciferase (reporter vector)/Renilla luciferase (cotransfectant control) readings.
Statistics
Statistical analysis of IMPROVE data and meta-analysis was performed using R version 3.0.2. 24 Linear regression was used to assess genotypic association with continuous variables (IMT variables were log-transformed before analysis because of skewed distributions), whereas logistic regression was used to assess binary traits, such as plaque presence. Cox proportional hazard model was used to assess time-to-event data, having confirmed that the proportional hazard assumption was satisfied. These analyses used an additive genetic model. Analyses in IMPROVE controlled for age, sex (where appropriate), and multidimensional scaling coordinates (because of population substructure). Meta-analysis looked at genotypic association with common cIMT (the variable available in all cohorts) separately in men and women using a random effects model. Pooled regression coefficients with 95% confidence intervals were calculated. Five cohorts were studied: PLIC, IMPROVE, Whitehall II, MDC, and EAS. The latter 3 cohorts were used for replication in the original study of Gertow et al. 8 Statistical analysis of PLIC data was performed using SPSS® v.19.0 for Windows® (IBM Corporation®, Chicago IL) program. The Shapiro-Wilk test was performed to verify the normal distribution of linear variables. Statistical analyses were performed on log-transformed cIMT variables because of skewed distributions. Association between the rs4888378 SNP and continuous variables, adjusting for age and smoking, was performed by linear regression and ANCOVA (SPSS, General Linear Model) with Bonferroni post hoc analysis. Analyses were controlled for age and sex (where appropriate).
Results
Association of rs4888378 With IMT Progression in PLIC
We first investigated the association of cIMT with rs4888378 in another cohort, allowing us also to look at the related phenotype of cIMT progression. The PLIC study was used for replication, comprising 2015 general population subjects from Italy. Study characteristics for PLIC and IMPROVE are summarized in Tables I and II .072, P=0.788). Overall, no association of rs4888378 was seen with basal common cIMT in PLIC (P=0.518) nor with annual common cIMT progression over 6-year follow-up (P=0.451, ANCOVA; adjusted for age, sex, and smoking). In women only, however, annual common cIMT progression over 6-year follow-up was 10% lower for each protective A allele (AA versus GG, P=0.04, ANCOVA and Bonferroni post hoc analysis), whereas no significant association was seen in men (P=0.940; Figure 2 ).
Interestingly, rs4888378 was associated with the risk factors of waist circumference (P=0.030) and waist/hip ratio Table; model adjusted as above), the minor A allele being associated with higher values of both. In women, the SNP was also associated in the same direction with body mass index (BMI), hip circumference, and glucose; in men, only hip circumference showed an association, with the lower risk A allele here being seen with smaller circumference (Tables VI and VII in the Data Supplement).
Sex Differences in Genotypic IMT Association and Cardiovascular Events
The differences between men and women seen in PLIC prompted additional analysis into sex-specific associations. A meta-analysis was performed on the association of rs4888378 with common cIMT in men and women, using PLIC, IMPROVE, and 3 replication cohorts used in the original study of Gertow et al. In women, rs4888378 was associated with IMT in the expected direction (a decrease of 0.0047 mm for each A allele; P=1.63×10 -4 ), whereas in men no significant association was found (β=−0.0029; P=0.0678; Figure 3 ).
Combined vascular event rate (cardiac, cerebrovascular, or peripheral) was analyzed by sex in IMPROVE (these event data were not available in the replication cohorts), and again the association was only significant in women. Overall each A allele was associated with a reduction in hazard ratio of 23% (Cox proportional hazard model; P=0.01); in women, a reduction in hazard ratio of 36% (P=0.01), and in men, no significant association (reduction in hazard ratio, 14%; P=0.24; Figure II in the Data Supplement). IMT phenotypes by genotype in men and women in IMPROVE can be seen in Table  VIII in the Data Supplement.
Bioinformatics Analysis of rs4888378
After confirming rs4888378 phenotypic association in different cohorts and finding sex-specific associations, we looked for the functional variant to understand the mechanism behind the association. Although the lead SNP rs4888378 may itself be producing the functional effect causing cIMT, it may also be tagging a functional SNP in strong LD. LD analysis using A, Overall, despite a trend for lower ΔIMT with each A allele, no significant association was seen with genotype. B, In women only, ΔIMT in the AA genotype was lower than in the GG genotype (P=0.04), although the overall trend was not significant. C, In men only, no trend or significant association was seen. ≥0.8) with rs4888378 ( Figure 4 ), spanning the genes CFDP1, TMEM170A, and CHST6 and implicating any of these SNPs as a candidate for the functional variant. Of these 214 variants, none were nonsynonymous, located within splice junctions or in predicted miRNA-binding sites, and functionality of the association was therefore likely to be because of effects on gene regulatory elements. Newer 1000 Genomes Project data later provided a further 56 variants in strong LD with rs4888378; however, these additional variants did not meet the defined selection criteria for further analysis. These variants were analyzed for their potential regulatory effects using ENCODE, Roadmap, and transcription factor binding motif data, as described in the Methods. Six variants passed the criteria and were selected for further analysis ( Figure 5 ).
Effect of Variants in LD With rs4888378 on DNAProtein Interactions
EMSA was performed to determine whether the 6 variants within potential regulatory elements were able to directly affect DNA-protein interactions. One SNP, rs4888378, demonstrated differential protein-binding by allele ( Figure 6A ; all SNPs shown in Figure III in the Data Supplement). The risk allele G bound several proteins strongly, whereas the protective A allele showed much weaker protein binding, suggesting that the minor allele weakens a binding site for a protein or protein complex.
To characterize the DNA-protein interaction, multiplexed competitor EMSA 22 was performed, entailing incubation of the nuclear extract with 70 unlabelled competitor DNA consensus sequences for well-characterized transcription factors, before addition of the rs4888378-labeled probe. This showed the protein binding to be competed out on addition of the Forkhead box protein A (FOXA) consensus sequence ( Figure 6B ). Although some other competitors were associated with a reduction in band intensity, they did not consistently compete out the band. Comparing the FOXA-binding motif to the genomic sequence around rs4888378 reveals them to match up well, and for the A allele to weaken the binding motif ( Figure 7 ).
Effect of rs4888378 on Reporter Gene Expression
The ability of rs4888378 to affect gene expression was assessed using luciferase reporter assays, where a 379 bp fragment containing either allele was inserted downstream of the luciferase gene in a pGL3-promoter vector, to act as Data from 1000 Genomes (Pilot 1); graph plotted with data and script from SNP Annotation and Proxy Search. 18 Lead SNP rs4888378 is shown in red; other SNPs are shown relative to their position at the locus (x axis) and linkage disequilibrium (LD; r 2 ) with rs4888378 (y axis). The majority of strong LD SNPs lie within CFDP1 and TMEM170A; they may affect these genes, or lie within enhancer regions which affect expression of other genes. Chromosome coordinates are based on NCBI Build 36.1 (hg18).
an enhancer or repressor. This initial fragment inserted into the pGL3-promoter vector resulted in a decrease in expression compared with control vector (pGL3 promoter) for both rs4888378 alleles ( Figure IV in the Data Supplement); we considered that this decrease may be caused by a repressor protein binding to part of the sequence of the inserted fragment. Bioinformatics sequence analysis using MatInspector predicted the binding of 3 repressors and related proteins to the sequence fragment: E4 Promoter-Binding Protein 4 (E4BP4), cell cycle genes homology region (CHR), and PR domain containing 1 (PRDM1) ( Figure 1A) ; 3 further insertions were thus designed to investigate the effect of these potential DNA-protein interactions on gene expression ( Figure 1B-1D ). Allele-specific expression was observed from vectors with insertions 3 and 4 ( Figure 1C and 1D ; P=5.7×10 -2 ; P=4.0×10 -22 ), with a nonsignificant trend in the third ( Figure 1B) . Effect size and direction were dependent on fragment size, whereas expression with allele G remained similar in all cases, allele A showed a 35% and 92% reduction in expression compared with G in the shorter fragments.
While considering the cell type to use, we also selected human umbilical vein endothelial cells, a relevant choice as blood vessel endothelial cells. However, we could not achieve sufficient transfection efficiency of the reporter vector in these cells. We used Huh7 cells because of their reliable performance in these assays, the fact that the genes of interest at the locus (BCAR1, CFDP1, TMEM170A and LDHD) are expressed in liver cells, 21 and that ENCODE regulatory signals, such as open chromatin, are similar between endothelial and hepatoma cells.
Expression Quantitative Trait Loci Analysis
It had previously been shown that rs4888378 was associated with at least nominal significance with mRNA expression of TMEM170A, BCAR1, and LDHD in aortic media, aortic adventitia, and carotid plaque. 8 To extend this analysis, we used the publicly available gene expression data set GTEx. Of the 9 genes at the locus tested on GTEx, 3 showed nominally significant allele-specific expression with rs4888378 (BCAR1, ZNRF1, and TMEM170A; Figure 8 after correction for multiple testing (Figure 8) , with expression of BCAR1 increasing with each higher-risk G allele. These expression levels are relevant to IMT and plaque, as BCAR1 has been shown to be expressed at the protein level in cells involved in atherosclerosis. 25 Although analysis could not be separated by sex in GTEx, further analysis of tissue expression data in ASAP 8 did not indicate the association of rs4888378 with TMEM170A and LDHD to be specific to women; the relationship was significant in men but not in women ( Figure VI in the Data Supplement). However, the small sample size of women precluded assessment of any association.
Discussion
In this study, we have investigated a locus on chromosome 16 previously associated with cIMT and coronary artery disease. Replication and additional analysis showed the locus association with common cIMT and vascular events to be present only in women. Using bioinformatics and evidence from differential protein binding and allele-specific gene expression, we considered several variants in strong LD with the locus lead SNP; however, detailed analysis suggested the original lead SNP as the potentially functional SNP. Tissue expression data indicate that the promoter of this SNP may be acting on is BCAR1, providing new insight about the mechanism of the causal SNP's effect on atherosclerosis. Although the IMT association was replicated in other cohorts in Gertow et al, 8 here the lead SNP rs4888378 was not associated with basal common cIMT in PLIC. However, it was associated with common cIMT progression over 6-year follow-up, but only in women. Meta-analysis looked at the genotype-IMT relationship separately in men and women in IMPROVE, PLIC, and 3 original replication cohorts: a genotypic association was seen only in women. Vascular event rate in IMPROVE was also associated with genotype only in women. This raises questions about how physiological differences between the sexes may interact with genotype to affect IMT and cardiovascular disease. Bioinformatics and functional analysis were then used to investigate the locus to look for a functional SNP. Regulation data from ENCODE and RoadMap Epigenomics were used to evaluate the 215 variants in strong LD for their regulatory potential. Updated 1000 Genomes data became available following completion of initial analysis; LD was recalculated and 56 new variants found. However, none passed the threshold for further analysis. Several relevant tracks were interrogated to create a shortlist of potentially functional variants. Chromatin immunoprecipitation sequencing produced peaks of transcription factor binding sites, in which we might expect variants to affect transcription factor (TF) binding and action. Histone methylation and acetylation marks showed areas consistent with promoters and enhancers. Formaldehyde-assisted isolation of regulatory elements (FAIRE) and DNase hypersensitivity showed areas of open chromatin without associated histones, which are more likely to be involved in active expression. The ElDorado tool (Genomatix) used transcription factor motif sequences to identify variants that might facilitate or block TF binding.
Of the shortlist of candidate SNPs assayed using EMSA, only the lead SNP rs4888378 showed allele-specific protein binding, with a protein binding strongly to the risk G allele. We therefore hypothesize that a transcriptional activator binds more strongly to this sequence when the G allele is present, activating an atherogenic gene at the locus, resulting in increased IMT. Alternatively, a repressor may bind more strongly, reducing expression of a gene that is atheroprotective.
Multiplexed competitor EMSA implicated FOXA as the protein family that may be binding. FOXA is a subfamily of Figure 7 . FOXA consensus sequence used in multiplex competitor electrophoretic mobility shift assay compared with genomic sequence around rs4888378. The single nucleotide polymorphism G allele matches more closely with the consensus sequence, suggesting FOXA may be the protein binding here. Figure 8 . BCAR1 expression by rs4888378 genotype in (A) aortic artery and (B) tibial artery. Data and graph from Genotype-Tissue Expression Portal. 21 Of the 9 genes analyzed at the locus, only BCAR1 remained significant after correction for multiple testing; expression of BCAR1 increased with each allele of the high-risk G allele. eQTL indicates expression quantitative trait loci.
hepatocyte nuclear factors consisting of FOXA1, FOXA2, and FOXA3, which share a common consensus sequence. These factors act as transcriptional activators for liver-specific genes and may have roles in regulation of metabolism. 26 The luciferase reporter assay can provide insight into the mechanism and action of the SNP and evaluate how different protein binding may affect gene expression.
The in vivo expression data from ASAP and GTEx suggest that the A allele is associated with lower expression. We showed that expression in vitro was also lower with the A allele. However, the magnitude of the difference varied with inserted fragment size, highlighting the strong effect that proteins binding in vitro to proximal sequence elements can have on enhancer or repressor activity. As shown in Figure 1 , the fragments were designed to include or exclude the predicted binding sites for 3 repressor-related proteins. Fragments 3 and 4, showing a significant decrease in expression with allele A, excluded the E4BP4 (NFIL3) binding site, a transcriptional repressor that binds to activating transcription factor sites in many promoters. 27 The interaction between inserted fragment length and genotype implies interaction between proteins binding to sequence elements around the SNP. Although this evidence does not prove the effect of E4BP4 at the locus, it suggests the presence of a binding protein, which can suppress the effect of the SNP under certain circumstances.
Selection of the most representative fragment for assaying expression is complicated by the differences between in vitro assay and in vivo conditions. Nevertheless, rs4888378 had a reproducible and strong effect on gene expression. The SNP may be affecting enhancer activity to alter expression of 1 or more of the genes at this locus, but it is not clear yet which promoter or promoters it affects.
The effect of rs4888378 on expression prompted more study of in vivo expression data. As published by Gertow et al, 8 expression assays in relevant tissues from the ASAP and BiKE studies revealed associations of rs4888378 genotype with the expression of 3 genes within 200 kb: TMEM170A in aortic intima-media and adventitia, and nominal significance with BCAR1 in carotid plaque and LDHD and aortic intima-media and adventitia. The protective minor allele was associated with lower TMEM170A and BCAR1 expression and higher LDHD expression. Although there is a possibility of false positives because of multiple testing, the association with multiple genes supports the idea that rs4888378 may be present in an enhancer acting on multiple promoters.
To investigate further allele-specific expression with rs4888378, we looked at tissue expression data from the GTEx portal, 21 a resource to combine gene expression data from multiple tissues with information about genetic variation, to identify expression quantitative trait loci. We looked at GTEx expression data in aortic artery and tibial artery tissues. Of the genes analyzed, only BCAR1 showed allelic differences in expression in both tissues and remained significant after correction for multiple testing (Figure 8 ). The relationship was in the same direction as that seen in BiKE, with the protective A allele associated with lower expression.
In addition to reinforcing relationships seen previously, this result is particularly interesting because of the known functions of BCAR1. Because of its roles in cell adhesion and proliferation in cells such as vascular smooth muscle cells, Gertow et al speculated that the causal variant may be regulating transcription of BCAR1 in vascular smooth muscle cells, a proposal here strengthened by gene expression data, which show the protective A allele to be associated with lower expression of BCAR1 and the luciferase reporter data show it to drive lower gene expression. It has since been shown that BCAR1 is involved in PDGF stimulation of VSMC migration, and its expression and phosphorylation promote formation of neointima after arterial injury. 25 We therefore hypothesize that the risk G allele increases expression of BCAR1 stimulating VSMC migration and increasing the formation of neointima in the vessel wall, resulting in larger plaques and greater cIMT.
The implication of BCAR1 in the phenotype is particularly interesting when we consider the sex-specific associations with common cIMT, IMT progression, and vascular events. Men have a higher overall risk of CHD, 28 and although differences between the sexes in traditional risk factors contribute to this disparity, sex remains associated over and above the known risk factors. 29 What could be causing differences in CHD pathology between men and women, such that certain genetic variants more strongly affect women? Of cardiovascular risk factors, only female hormonal status has been shown to be sex-specific. 30 Oestrogen is thought to have a protective effect; as it decreases after menopause, low-density lipoprotein, total cholesterol, and triglyceride levels increase, promoting atherogenesis. 31 In addition to its effects on blood lipid profile, oestrogen may also have a direct effect on endothelial cell function, with oestrogen therapy being associated with enhanced fibrinolytic potential. 32 Reduced plasma fibrinolytic activity has been shown to be a marker of CVD risk. 33 It could be hypothesized that an interaction exists between the effect of oestrogen of endothelial cells during plaque formation and the variant's effect on plaque. The implication of BCAR1 by genotypeexpression level associations suggests that this interaction could occur through BCAR1's known role in endothelial and vascular smooth muscle cells. Of particular note is that the BCAR1 protein is already known to have connections with oestrogen: it was characterized under the name breast cancer antiestrogen resistance 1 when overexpression was found to confer antiestrogen resistance in breast cancer cells. 34 It seems a strong candidate for both effects on atherosclerosis and interactions with sex.
A limitation was that the relationship with basal IMT was not replicated in PLIC, an association only being seen with IMT progression. Patients with higher levels of risk factors are more likely to accumulate higher IMT and suffer cardiovascular events, increasing the chance of seeing SNP-associated differences in IMT. Patients with more severe atherosclerosis may also experience different effects of the SNP on IMT to those with little atherosclerosis. Alternatively, the number of females in PLIC (1076 compared with 1931 in IMPROVE, and a lower genotyping call rate), reduced the power to detect such an association. Larger cross-sectional studies in women from the general population may be required. Furthermore, the perimeter and technique of cIMT studies may differ between studies and contribute to variability and loss of power.
Numerous studies have related cIMT measures to increased CVD risk 11, 35, 36 but the use of cIMT as a predictor of cardiovascular events is still debated. A meta-analysis showed that adding common cIMT to the Framingham Risk Score did not improve the 10-year risk prediction by a clinically significant amount. 37 As no association was found between rs4888378 and cardiometabolic risk factors in IMPROVE, the association with weight, BMI, and glucose levels in PLIC was unexpected, as was the direction of effect, with the protective IMT allele being associated with higher risk parameters. BMI is associated with cIMT, as would be expected, BMI being strongly associated with CHD over and above the effect of its correlation with other cardiovascular risk factors. 38, 39 However, the protective genotype is associated here with higher BMI, and no such association is seen in IMPROVE. This discrepancy may be because of the cohorts' differing characteristics (high risk versus general population), but the unexpected direction and failure to replicate the effect suggest that the observed association may have occurred by chance and that the variant's mechanism of action is not related to adiposity or related measures, such as BMI.
Unavoidable limitations also exist when looking at LD blocks, as statistical data cannot separate out the effects of variants in complete LD. However, regulatory annotation data from ENCODE and summary tools, such as HaploReg v2, 40 here facilitated selection of candidate functional SNPs. Although at present, there is no conclusive tool to rank noncoding variants by likelihood of functionality, programs such as RegulomeDB 41 and CADD 42 provide their own ratings using the growing genomic annotation by projects, such as ENCODE 9 and RoadMap. 19 We have also demonstrated the use of functional assays, such as EMSA. Although EMSA examines variants outside their natural chromatin environment and cannot not take into account in vivo properties, such as chromatin state, its capacity to detect allele-specific effects without the hindrance of LD is valuable. Multiplexed competitor EMSA can identify proteins binding to a sequence; although an EMSA-verified antibody for FOXA was not available here, supershift EMSA with antibody would often be a valuable step to confirm specific protein binding.
The luciferase reporter assay also occurs in vitro, without measuring local and long-distance interactions chromatin state. Selecting a representative enhancer fragment is therefore difficult; this emphasizes the value of assaying multiple sequence fragments encompassing the SNP as performed in our study. Further assays would ideally focus on more atherosclerosis-relevant cell lines, such as human umbilical vein endothelial cells, which we could not assay because of low transfection efficiency of the reporter vector.
High gene density and LD at the locus makes it more difficult to isolate the specific promoter that rs4888378 may be acting on. As it regulatory elements may act over long distances, 43 further work should consider that SNPs may have regulatory effects on more distal genes. ENCODE tracks showing chromatin conformation capture carbon copy (5C) and chromatin interaction analysis with paired-end tag showing long-range chromatin interactions do not currently show rs4888378 to interact with any distal sites, although data are preliminary: 5C data are still in its pilot stages and chromatin interaction analysis with paired-end tag only has data available for cancer cell lines.
The study illustrates the difficulty of searching for functional variants in strong LD blocks. The ideal method to discriminate causal variants would be to separate out SNP association signals in strong LD blocks. Although association studies on the cohorts that have already been used cannot achieve this, the use of cohorts containing ethnic groups other than Europeans, with different LD patterns, would produce different association signals surrounding functional variants. This would be of particular value in African populations, with shorter haplotype blocks and thus smaller groups of SNPs in LD. 44 To achieve this, future cohort studies would need to diverge from the current model of largely European-based cohorts.
Despite the obstacles of LD and uncertainty of regulatory behavior, this study has identified a potentially functional variant for the association of the chromosome 16 locus with cIMT and CVD risk using bioinformatics and functional assays. Analysis of expression data suggests BCAR1 may be the gene of interest, and further analysis suggests that the effect on common cIMT and vascular events is present in women only. The protective effect of oestrogen on atherosclerosis and the role of both oestrogen and BCAR1 in endothelial cell function suggest a possible interaction between the 2 that may be involved in the mechanism of the variant's effect on atherosclerosis and CVD risk.
